Results 281 to 290 of about 199,183 (334)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza   +27 more
wiley   +1 more source

Next release of the European Marine Omics Biodiversity Observation Network (EMO BON) shotgun metagenomic data from water and sediment samples (Release 2). [PDF]

open access: yesBiodivers Data J
Santi I   +61 more
europepmc   +1 more source

Education : Basque

open access: yes, 2015
openaire   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

open access: yesHIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux   +15 more
wiley   +1 more source

Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein. [PDF]

open access: yesMycopathologia
Bregón-Villahoz M   +7 more
europepmc   +1 more source

Characterization of the Lipidome of Neurons in Mouse Brain Nuclei Using Imaging Mass Spectrometry. [PDF]

open access: yesAnal Chem
Huergo C   +5 more
europepmc   +1 more source

The Risk of Transmission of Genetic Prion Diseases is Greater Than 50. [PDF]

open access: yesEur J Neurol
Kortazar-Zubizarreta I   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy